Loading...
Market
How will Organon's stock price change by December 31, 2024, post-acquisition of Dermavant?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Stock market data from financial news sources like Bloomberg, Reuters
Story
Organon to Acquire Dermavant and VTAMA Cream in $175 Million APA Deal
Sep 18, 2024, 11:35 AM
Organon has announced its acquisition of Dermavant, including its innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. The deal includes an upfront payment of $175 million, with additional payments up to $1.2 billion based on sales milestones. An additional $75 million is contingent on VTAMA's approval in AtD. This acquisition, structured as an APA, highlights Organon's commitment to expanding its dermatology portfolio.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Less than $25 • 25%
$25 to $29.99 • 25%
$30 to $34.99 • 25%
$35 or more • 25%
Yes • 50%
No • 50%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%
Alopecia treatment • 25%
Psoriasis treatment • 25%
Eczema treatment • 25%
Other • 25%
Strong Buy • 25%
Buy • 25%
Hold • 25%
Sell • 25%
Stock price increases by more than 10% • 25%
Stock price increases by 0-10% • 25%
Stock price decreases by 0-10% • 25%
Stock price decreases by more than 10% • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Yes • 50%
No • 50%